Patent Application
20230323295
The present invention relates to a production method for microglia. Priority is claimed on Japanese Patent Application No. 2022-046010, filed Mar. 22, 2022, the content of which is incorporated herein by reference.
Cells of the central nervous system are difficult to obtain. On the other hand, various cells including cells of the central nervous system cells have become available by differentiating pluripotent stem cells such as induced pluripotent stem cells (iPSC) into cells of interest. Further, disease model cells can also be produced by differentiating pluripotent stem cells derived from a patient into cells of interest.
Microglia are one kind of glial cells of the central nervous system. Glial cells are a general term for cells that are not nerve cells that constitute the nervous system. Microglia are known as central immunocompetent cells. Unlike cells of the central nervous system, microglia are conceived to be derived from the mesoderm and play a role as immune cells in the brain. At the time in a disease state, microglia become activated, which involves cell body hypertrophy and cell proliferation. It is known that activated microglia change the expression of various molecules including receptors in the cell membrane, migrate to a lesion part, phagocytize damaged cells or extracellular proteins such as amyloid β protein, and produce humoral factors (an inflammatory factor, a cytotoxic factor, a nutritional factor, and the like). Microglia play a major role in the mechanisms of central nervous system diseases and thus have been suggested to be associated with Alzheimer’s disease.
However, a conventional method of producing microglia from pluripotent stem cells requires 30 or more days of culture in order to obtain microglia. Accordingly, an object of the present invention is to provide a technique for producing microglia from pluripotent stem cells in a short period of time.
A production method for microglia according to the present invention includes a step of introducing, into pluripotent stem cells, a nucleic acid including an open reading frame of a transcription factor that increases expression of a Complement C3 (C3) gene.
According to the present invention, it is possible to provide a technique for producing microglia from pluripotent stem cells in a short period of time.
In one embodiment, the present invention provides a production method for microglia, which includes a step of introducing, into pluripotent stem cells, a nucleic acid including an open reading frame of a transcription factor that increases expression of a Complement C3 (C3) gene.
As will be described later in Examples, the inventors of the present invention revealed that the production of microglia, which conventionally takes 30 days or longer, can be carried out within 14 days by the production method of the present embodiment. In addition, as will be described later in Examples, the microglia produced by the production method of the present embodiment have phagocytic activity and thus have a function of microglia.
In microglia, microglial marker genes are expressed, and a function of microglia, such as phagocytic activity, is exhibited. Examples of the microglial marker gene include Purinergic Receptor P2Y12 (P2RY12), Complement C3 (C3), C-X3-C Motif Chemokine Receptor 1 (CX3CR1), Colony Stimulating Factor 1 Receptor (CSF1R), Alpha-2-Macroglobulin (A2M), ADAM Metallopeptidase Domain 28 (ADAM28), Plexin Domain Containing 2 (PLXDC2), Lysosomal Protein Transmembrane 5 (LAPTM5), Solute Carrier Organic Anion Transporter Family Member 2B1 (SLCO2B1), and Lymphocyte Antigen 86 (LY86), which will be described later in Examples.
The NCBI accession number of the nucleotide sequence of cDNA of the human P2RY12 gene is NM_022788.5, NM_176876.3, or the like. The NCBI accession number of the nucleotide sequence of cDNA of the human C3 gene is NM_000064.4. The NCBI accession number of the nucleotide sequence of cDNA of the human CX3CR1 gene is NM_001171171.2, NM_001171172.2, NM_001171174.1, or the like. The NCBI accession number of the nucleotide sequence of cDNA of the human CSF1R gene is NM_001288705.3, NM_001349736.2, NM_001375320.1, or the like. The NCBI accession number of the nucleotide sequence of cDNA of the human A2M gene is NM_000014.6, NM_001347423.2, NM_001347424.2, or the like. The NCBI accession number of the nucleotide sequence of cDNA of the human ADAM28 gene is NM_001304351.2, NM_014265.6, NM_021777.5, or the like. The NCBI accession number of the nucleotide sequence of cDNA of the human PLXDC2 gene is NM_001282736.2, NM_032812.9, or the like. The NCBI accession number of the nucleotide sequence of cDNA of the human LAPTM5 gene is NM_006762.3. The NCBI accession number of the nucleotide sequence of cDNA of the human SLCO2B1 gene is NM_001145211.3, NM_001145212.3, NM_007256.5, or the like. The NCBI accession number of the nucleotide sequence of cDNA of the human LY86 gene is NM_004271.4.
In the production method of the present embodiment, examples of the pluripotent stem cell include an embryonic stem cell (an ES cell) and an induced pluripotent stem cell (an iPS cell). The pluripotent stem cell is preferably a human cell.
Examples of the transcription factor that increases the expression of the C3 gene include Spi-1 Proto-Oncogene (SPI1), CCAAT Enhancer Binding Protein Alpha (CEBPA), Platelet Activating Factor Receptor (PTAFR), Fli-1 Proto-Oncogene, ETS Transcription Factor (FLI1), Myocyte Enhancer Factor 2C (MEF2C), Early Growth Response 2 (EGR2), RUNX Family Transcription Factor 1 (RUNX1), Tumor Necrosis Factor (TNF), CCAAT Enhancer Binding Protein Beta (CEBPB), IKAROS Family Zinc Finger 1 (IKZF1), Kruppel Like Factor 6 (KLF6), Nuclear Factor I C (NFIC), E74 Like ETS Transcription Factor 4 (ELF4), Paired Box 8 (PAX8), PR/SET Domain 1 (PRDM1), Myocyte Enhancer Factor 2A (MEF2A), and Nuclear Receptor Subfamily 4 Group A Member 3 (NR4A3).
The NCBI accession number of the nucleotide sequence of cDNA of the human SPI1 gene is NM_001080547.2, NM_003120.3, or the like. The NCBI accession number of the nucleotide sequence of cDNA of the human CEBPA gene is NM_001285829.1, NM_001287424.2, NM_001287435.1, or the like. The NCBI accession number of the nucleotide sequence of cDNA of the human PTAFR gene is NM_000952.5, NM_001164721.2, NM_001164722.3, or the like. The NCBI accession number of the nucleotide sequence of cDNA of the human FLI1 gene is NM_001167681.3, NM_001271010.2, NM_001271012.2, or the like. The NCBI accession number of the nucleotide sequence of cDNA of the human MEF2C gene is NM_001131005.2, NM_001193347.1, NM_001193348.1, or the like. The NCBI accession number of the nucleotide sequence of cDNA of the human EGR2 gene is NM_000399.5, NM_001136177.3, NM_001136178.2, or the like. The NCBI accession number of the nucleotide sequence of cDNA of the human RUNX1 gene is NM_001001890.3, NM_001122607.2, NM_001754.5, or the like. The NCBI accession number of the nucleotide sequence of cDNA of the human TNF gene is NM_000594.4. The NCBI accession number of the nucleotide sequence of cDNA of the human CEBPB gene is NM_001285878.1, NM_001285879.1, NM_005194.4, or the like. The NCBI accession number of the nucleotide sequence of cDNA of the human IKZF1 gene is NM_001220765.3, NM_001220767.2, NM_001220768.2, or the like. The NCBI accession number of the nucleotide sequence of cDNA of the human KLF6 gene is NM_001160124.2, NM_001160125.2, NM_001300.6, or the like. The NCBI accession number of the nucleotide sequence of cDNA of the human NFIC gene is NM_001245002.2, NM_001245004.2, NM_001245005.2, or the like. The NCBI accession number of the nucleotide sequence of cDNA of the human ELF4 gene is NM_001127197.2, NM_001421.4, or the like. The NCBI accession number of the nucleotide sequence of cDNA of the human PAX8 gene is NM_003466.4, NM_013951.3, NM_013952.4, or the like. The NCBI accession number of the nucleotide sequence of cDNA of the human PRDM1 gene is NM_001198.4, NM_182907.3, or the like. The NCBI accession number of the nucleotide sequence of cDNA of the human MEF2A gene is NM_001130926.5, NM_001130927.5, NM_001130928.4, or the like. The NCBI accession number of the nucleotide sequence of cDNA of the human NR4A3 gene is NM_006981.4, NM_173199.4, or the like.
As will be described later in Examples, in a case of introducing nucleic acids containing open reading frames of these transcription factors into pluripotent stem cells, it is possible to induce differentiation into microglia. It is noted that the method of transfecting transcription factors into pluripotent stem cells to induce differentiation is also called forward programming. Nucleic acids containing open reading frames of these transcription factors may be used singly or in a combination of two or more thereof.
The nucleic acids containing open reading frames of these transcription factors may be mRNA or an expression vector. In addition, the expression vector may be a virus vector or may be a plasmid vector.
In the production method of the present embodiment, the transcription factor that increases the expression of the C3 gene preferably includes at least CEBPA, and it is preferably two or more transcription factors including at least CEBPA.
Examples of the more specific combination of transcription factors that increase the expression of the C3 gene include combinations of 2 to 5 transcription factors, which include CEBPA, CEBPB, KLF6, NFIC, or PAX8 among SPI1, CEBPA, PTAFR, FLI1, MEF2C, EGR2, RUNX1, TNF, CEBPB, IKZF1, KLF6, NFIC, ELF4, PAX8, PRDM1, MEF2A, NR4A3.
Examples of the still more specific combination of transcription factors that increase the expression of the C3 gene include a combination of CEBPA, MEF2C, and PAX8, a combination of CEBPA, CEBPB, and PAX8, a combination of CEBPA, NFIC, and PAX8, a combination of CEBPA and PAX8, a combination of CEBPB, KLF6, and PAX8, a combination of KLF6, NFIC, and PAX8, a combination of PTAFR, CEBPB, and PAX8, and a combination of CEBPA, KLF6, and PAX8.
As will be described later in Examples, in the production method of the present embodiment, the culture medium for culturing pluripotent stem cells introduced with a nucleic acid containing an open reading frame of a transcription factor is not particularly limited.
In one embodiment, the present invention provides microglia produced by the production method described above. Due to being characterized by the production method, the microglia of the present embodiment are conceived to have a different gene expression profile and the like as compared with microglia obtained by inducing differentiation by other methods or microglia in vivo. However, it is very difficult and impractical to identify such a difference and identify whether or not it is the microglia of the present embodiment based on the difference in gene expression profile or the like. For this reason, it is realistic to carry out the identification by the production method.
With reference to published papers, a unique weighting was carried out to select a gene set capable of serving as microglia markers. Table 1 shows the set of microglial marker genes selected by the inventors of the present invention.
With reference to published papers, transcription factors for microglial differentiation were selected, where the transcription factors were conceived to be suitable for inducing differentiation into microglia. More specifically, transcription factors were selected, where the transcription factors were conceived to promote the expression of the microglial marker genes shown in Table 1 above in a case of being introduced into pluripotent stem cells. Table 2 below shows a list of transcription factors for microglial differentiation selected by the inventors of the present invention. For simplification, each gene is represented by one letter of the alphabet from “A” to “Q”.
Using the 17 kinds of transcription factors shown in Table 2, it was checked whether or not iPS cells could be induced to differentiate into microglia by forward programming of transfecting transcription factors into iPS cells. First, as a primary evaluation, the transcription factors shown in Table 2 above were transfected into iPS cells in 384 combinations shown in Table 3 below, and gene expression analysis was carried out.
HPS 1005 1383D2 (RIKEN BRC) was used as an iPS cell. StemFit AK02N (Ajinomoto Co., Inc., AJ100, hereinafter may be referred to as “StemFit”) was prepared according to the manufacturer’s instructions. CultureSure Y-27632 (FUJIFILM Wako Pure Chemical Corporation, 036-24023) was prepared to 10 mM with dimethylsulfoxide (DMSO). A coating solution was prepared by diluting iMatrix-511 silk (Takara Bio Inc., 892021) to 0.5 µg/cm2 with phosphate-buffered saline (PBS) (-), and 20 mL of the coating solution was added to each of four 150 mm dishes and precoated at 37° C. for 1 hour.
After 1 hour, the coating solution was aspirated, Cells were seeded to 5.0 × 105 cells per dish using a culture solution obtained by adding a 1/1,000 volume of 10 mM CultureSure Y-27632 to StemFit (hereinafter, may be referred to as “Medium SY”), and the culture was carried out at 37° C. in 5% CO2 until an appropriate cell number was reached. From the day after seeding, the culture medium was replaced using StemFit.
A 96-well plate was used for iPS cell culture. All wells of twelve 96-well plates were precoated with iMatrix-511 silk (Takara Bio Inc., 892021) at a concentration of 0.5 µg/cm2, and aspiration was carried out immediately before seeding iPS cells.
The iPS cells cultured in a 150 mm dish were washed with PBS (-), a solution obtained by mixing equal volumes of TrypLE Select (1X) (Thermo Fisher Scientific, Inc., 12563-029) and 0.5 mmol/L-EDTA/PBS solution (Nacalai Tesque, Inc., 13567-84) was added incubated at 37° C. for 5 minutes, and then the cells were carefully stirred with a 1,000 µL micropipette to detach the cells from the dish and collected in a centrifuge tube.
The same amount of Medium SY as that of the cell suspension was added into the centrifuge tube, in which the cell suspension had been collected, to stop the TrypLE Select reaction. After centrifugation at 200 × g for 3 minutes, the supernatant was aspirated to prepare a soft pellet, the pellet was loosened by tapping, and then Medium SY was added thereto to resuspend the cells.
Viability and cell number were measured by Countess (Thermo Fisher Scientific, Inc.), and cell suspensions having three concentration levels of 1.79 × 105 cells/mL, 3.04 × 105 cells/mL, and 4.30 × 105 cells/mL were prepared with Medium SY to prepare a confluency condition proper for transfection.
Aliquots of 100 µL of the cell suspension at each concentration were dispensed into the four coated 96-well plates to prepare four 96-well plates per concentration level for three concentration levels, and the culture was carried out at 37° C. in a 5% CO2 environment.
Transcription factors were transfected in the form of mRNA. The mRNA was thawed on ice and prepared to a concentration of 0.1 µg/µL, and four sets of mRNA mix stocks were prepared by mixing 0.5 µL with the combinations shown in Table 3 above to be 1.5 µL and kept frozen at -80° C. until the used in the transfection.
One day after iPS cell seeding (Day 1), four plates having a concentration level of 70% to 90% confluency were selected, the culture medium was replaced with StemFit, and the culture was carried out at 37° C. in a 5% CO2 environment until transfection was carried out.
The temperature of Opti-MEM I Reduced Serum Medium (Thermo Fisher Scientific, Inc., 31985062, hereinafter may be referred to as “Opti-MEM”) was returned to room temperature, and the mRNA mix stock was thawed on ice over 30 minutes.
A Mix 1 solution was prepared by mixing, per well of a 96-well plate, 1.5 µL of Lipofectamine Messenger MAX (Thermo Fisher Scientific, Inc., LMRNA001) in 36.7 µL of Opti-MEM and incubated at room temperature for 10 minutes. Next, a Mix 2 solution was prepared by adding 1.5 µL of the mRNA mix to 36.7 µL of Opti-MEM and carrying out mixing by tapping.
Subsequently, 12 µL of the Mix 2 solution was mixed with 12 µL of the incubated Mix 1 solution by pipetting to prepare a transfection solution, which was subsequently incubated for 5 minutes at room temperature. Subsequently, 20.8 µL of the transfection solution prepared according to the combination of mRNAs shown in Table 3 above was added dropwise to each well of the four 96-well plates seeded with iPS cells, and incubation was carried out for 3 hours at 37° C. in a 5% CO2 environment. After 3 hours, the whole amount of StemFit was replaced, and incubation was carried out for 2 hours at 37° C. in a 5% CO2 environment.
After 2 hours, the same transfection operation was carried out once again, incubation was carried out overnight at 37° C. in a 5% CO2 environment, and two further times of transfection were carried out on Day 2, whereby transfection was carried out four times in total.
On Day 3, all 384 wells of the four 96-well plates that had been subjected to the differentiation induction were subjected to RNA-seq. RNA-seq was carried out according to the Smart-seq2 method (Picelli S., et al., Full-length RNA-seq from single cells using Smart-seq2, Nat Protoc., 9 (1), 171-181, 2014.) and the Quartz-seq2 method (Sasagawa Y., et al., Quartz-Seq2: a high-throughput single-cell RNA-sequencing method that effectively uses limited sequence reads, Genome Biol., 19 (1), 29, 2018.).
Transcriptome data worthy of analysis were obtained from 354 samples obtained by the Smart-seq2 method and 297 samples obtained by the Quartz-seq2 method, collectively from 379 samples among the 384 samples.
From the obtained transcriptome data, TPM (Transcripts per million) in Smart-seq2 and CPM (Counts per million, a value obtained by normalizing the number of UMI counts by 1,000,000) in Quartz-seq2 were subjected to heat mapping with log2, and the expression levels of seven genes of SLCO2B1, ADAM28, A2M, CSF1R, CX3CR1, C3, and P2RY12 were checked among the set of microglial marker genes shown in Table 1 above.
As a result of the analysis, according to the results of the Quartz-seq2 method, it was confirmed that C3 is expressed in almost all samples, followed by ADAM28 which is expressed in a large number of samples. In addition, from the results of the Smart-seq2 method, it was confirmed that although the observed TPM values are smaller than those of the Quartz-seq2 method, a large number of samples express C3. The above results suggested that iPS cells have differentiated into microglia-like cells in almost all combinations of transcription factors shown in Table 3 above.
As a result of the analysis, it was confirmed that, among the 384 combinations, a combination containing transcription factors such as B, E, I, L, and N, in terms of transcription factor symbol, has high expression levels of microglial marker genes.
Subsequently, each of the transcriptome data, which had been obtained by the Smart-seq2 method and the Quartz-seq2 method, were subjected to principal component analysis and factor analysis.
As a result of the analysis, it was confirmed that combinations of transcription factors with high expression of microglial marker genes are distributed on the positive side of PC1 by the principal component analysis and the positive side of Factor 2 by the factor analysis.
Based on each of the results of the principal component analysis and the factor analysis by the Smart-seq2 method and the Quartz-seq2 method and based on the expression levels of the marker genes in
Differentiation culture conditions were further investigated regarding the combination conditions of transcription factors. iPS cells were subjected to forward programming by transcription factor transfection with the combinations of transcription factors shown in Table 4, which had been determined to have a high ability to induce differentiation into microglia and were induced to differentiate with a culture medium for differentiation to induce differentiation into microglia, and the transcriptome analysis by RNA-seq was carried out.
A combination of transcription factors was transfected into iPS cells, which were subsequently induced to differentiate into microglia for 4 days in a culture medium for differentiation. As culture media for differentiation, the following three kinds of basal media were used: Neurobasal Media, DMEM/F-12, and Advanced DMEM/F-12. IL-34, M-CSF, GlutaMAX, and Component P were added to each of the basal media to obtain culture media designated as M1, M2, and M3. In addition, CD200, CX3CL1, and TGF-beta were added to M1, M2, and M3 to obtain culture media each designated as M4, M5, and M6. Table 5 below shows the compositions of the six kinds of the culture media M1 to M6.
Until transfection, differentiation culture was carried out in triplicate with respect to the six different culture media for differentiation under the 32 conditions of the 31 kinds of combinations of transcription factors shown in Table 4 above and ntfc (no transcription factor control) with culture medium for differentiation alone for checking the differentiation induction, where Nuclease-free Water was used instead of the mRNA mix in the ntfc.
Transfection was carried out according to the same protocol as in Experimental Example 3. A combination of two kinds of transcription factors of 0.75 µL was mixed at a concentration of 0.1 µg/µL to obtain 1.5 µL of an mRNA mix. In addition, in order to investigate a case of transfection with only one kind of transcription factor, 1.5 µL of the mRNA in Table 2 above was transfected at a concentration of 0.1 µg/µL. siPOU5F1 (Thermo Fisher Scientific, Inc., s10873) was added at 20 nM at the time of the preparation of all the first transfection solutions.
At the time of the culture medium replacement after the fourth transfection on Day 2, the culture medium was changed from StemFit to the culture medium for differentiation shown in Table 5 above. The culture medium for differentiation was replaced every other day, and all samples were subjected to RNA extraction on Day 7.
Samples transfected with only one kind of transcription factor were subjected to culture medium exchange to StemFit and then subjected to RNA extraction on Day 3.
Subsequently, RNA-seq was carried out by the Quartz-seq2 method. In addition, at the time of RNA-seq, total RNA extracted after the culture and total RNA extracted from the iPS cells collected at the time of seeding were used, and the following cells were used as controls: Human Microglia Primary Cell Culture Total RNA: 50 µg (Celprogen, 37089 RNA), Total RNA Human Monocytes, 1 µg (3H Biomedical, 3H100-30-10), Total RNA Human Dendritic Cells (MoDCs), 1 µg (3H Biomedical, 3H100-70-10), and Human Macrophage Primary Cell Culture-Frozen Vial (Celprogen, 36070-01). RNeasy mini kit (Qiagen, 74004) was used for the extraction of total RNA.
The expression levels of C3 and P2RY12 were checked regarding the UMI counts obtained by the Quartz-seq2 method.
In addition, in the iPS cells introduced with a combination of transcription factors including B, 1, K, L, and N, such as BLN, KLN, or IKN, C3 was highly expressed, and BLN was included in the top 50 samples regardless of the kind of culture medium for differentiation.
As a result of the classification, it was revealed that clusters 9 and 12 in
When the culture media for differentiation were compared, the clusters 7 and 10 were absent in Neurobasal-based M1 and M4. This suggested that samples induced to differentiate in a Neurobasal-based manner would not be in a transcriptome state similar to that of monocytes, dendritic cells, or macrophages.
When the samples distributed at positions close to the control of microglia were checked, BIN, CIN, BN, and BKN were frequently distributed.
In addition, the samples distributed close to monocytes, dendritic cells, and macrophages were ABD, AEI, BDF, DIJ, and DIP.
From the above results, the secondary evaluation using the culture media for differentiation revealed that a suitable method of carrying out differentiation into microglia is selecting a combination including B, I, K, L, and N, such as BLN, KLN, or IKN, from the transcription factor candidates in Table 2 above.
It was checked whether the phagocytic activity, which is a function of microglia, was exhibited in the combinations of transcription factors that were suggested to have a high microglia differentiation potential in the secondary evaluation.
Based on the results of the primary evaluation and the secondary evaluation, the induction of iPS cell differentiation into microglia with a combination of transcription factors BN, BEN, BIN, BLN, IKN, or KLN was evaluated. In addition, for comparison, a combination of transcription factors, AB, ABD, AEI, DIJ, or DIP, which provided a transcriptome state similar to that of the control hematopoietic cells, was also used to induce differentiation.
The differentiation induction conditions of Experimental Example 4 were scaled up to those for a 24-well plate, and the differentiation induction was carried out at N4 with each combination of transcription factors. M6 was used as the culture medium for differentiation. Similar to Experimental Example 4, differentiation was induced in the culture medium for differentiation M6 after four transfections. Subsequently, RNA was extracted from samples for N3 on Day 7 using the RNeasy mini kit, and RNA-seq was carried out by the Smart-seq2 method.
In addition, iCell microglia (FUJIFILM Wako Pure Chemical Corporation, C1110), in addition to the iPS cells at the time of seeding, the ntfc, and the microglia, the monocytes, and the dendritic cells the same as those used in Experimental Example 4, were cultured, and each total RNA was extracted as a control with the RNeasy mini kit. The remaining N1 was continuously cultured in the culture medium for differentiation M6 from Day 7, subcultured on Day 11, and cultured in the M6 culture medium to which Component P was not added. Subsequently, a time-lapse movie of 13 hours was taken overnight on Day 14 to check the phagocytic activity of the differentiated cells.
At the time of the RNA extraction on Day 7, adherent cells were few in AB, ABD, AEI, DIJ, and DIP, and ntfc. Therefore, floating cells were centrifuged to precipitate the cells and subjected together with the adherent cells to RNA extraction.
In the cDNA quality check by the Smart-seq2 method, it was confirmed that in the described above combinations of transcription factors and the microglial control (Celprogen), the chain length of cDNA is short, and thus the RNA quality is poor.
Among the microglia markers shown in Table 1 above, the expression levels of the following genes were confirmed: C3 and P2RY12, which are conceived to be important markers, in addition to APOE, BHLHE41, CABLES1, OLFML3, PROS1, SLC7A8, SLCO2B 1, TMEM119, and TREM2, which have been confirmed as genes specifically expressed microglia.
C3 was highly expressed in the microglia (Celprogen) and the iCell microglia. In addition, the combination of BN, BEN, BIN, BLN, IKN, or KLN, which was suggested to have a high ability to induce differentiation into microglia in Experimental Examples 3 and 4, reproduced a high expression level.
Further, in the microglial markers shown in
At the time of subculture on Day 11, adherent cells were few in AB, ABD, AEI, DIJ, DIP, and ntfc, and thus the subculture was carried out only on BEN, BIN, BLN, BN, IKN, and KLN. On Day 14, time-lapse imaging was carried out overnight for 13 hours using CQ1 (Yokogawa Electric Corporation).
From the above results, it was confirmed that iPS cells can be induced to differentiate into microglia in 14 days by transfecting a combination of transcription factors that increase the expression of C3 and other microglia-specific marker genes.
The present invention includes the following aspects.
A production method for microglia, including a step of introducing, into pluripotent stem cells, a nucleic acid including an open reading frame of a transcription factor that increases expression of a Complement C3 (C3) gene.
The production method according to [1], in which the transcription factor is selected from the group consisting of SPI1, CEBPA, PTAFR, FLI1, MEF2C, EGR2, RUNX1, TNF, CEBPB, IKZF1, KLF6, NFIC, ELF4, PAX8, PRDM1, MEF2A, and NR4A3.
The production method according to [2], in which the transcription factor includes at least CEBPA.
The production method according to [2] or [3], in which the transcription factor is two or more transcription factors including at least CEBPA.
While preferred embodiments of the invention have been described and illustrated above, it should be understood that these are exemplary of the invention and are not to be considered as limiting. Additions, omissions, substitutions, and other modifications can be made without departing from the scope of the invention. Accordingly, the invention is not to be considered as being limited by the foregoing description and is only limited by the scope of the appended claims.
| Number | Date | Country | Kind |
|---|---|---|---|
| 2022-046010 | Mar 2022 | JP | national |
